GERON CORP Long-term Purchase Commitment, Amount
GERON CORP (GERN) reported Long-term Purchase Commitment, Amount of $37.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermPurchaseCommitmentAmount · last filed 2026-08-05
- GERON CORP long-term purchase commitment, amount for the quarter ending 2026-06-30 was -$400.00K.
- GERON CORP long-term purchase commitment, amount for the quarter ending 2026-03-31 was $37.70M.
- GERON CORP long-term purchase commitment, amount for fiscal 2025 was $43.30M.
| Period end | Long-term Purchase Commitment, Amount 3 month | Long-term Purchase Commitment, Amount 6 month | Long-term Purchase Commitment, Amount 12 month |
|---|---|---|---|
| 2026-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $37.30M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $37.70M 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | $43.30M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |